|7. Start tofacitinib over an OSM (specifically apremilast) (PICO 55)|Very low|
|Conditional recommendation based on very-low-quality evidence; may consider starting an OSM (specifically apremilast) if the patient has recurrent infections.| |
|In adult patients with active PsA and predominant enthesitis despite treatment with OSM,| |
|8. Switch to a TNFi biologic over an IL-17i biologic (PICO 53)|Low (72, 73, 76, 89, 90, 92)|
|Conditional recommendation based on low-quality evidence; may consider switching to an IL-17i if the patient has severe psoriasis or contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease.| |
|9. Switch to a TNFi biologic over an IL-12/23i biologic (PICO 52)|Low (72, 73, 76, 98, 100)|